August 11, 2016

Retinal conditions: anti-VEGF injections

Query 15-11: Intravitreal bevacizumab for retinal conditions: real-world safety assessment

This project was originated with a query by CADTH and funded in June 2016 for one year. The objective of this study is to examine ocular complications of anti-VEGF injections given for neovascular age-related macular degeneration (AMD) and other retinal conditions in population-based cohorts.

In previous analysis, we reported the risk of primary and secondary outcomes in the AMD and the diabetic retinopathy cohorts. Analysis with MarketScan database was finalized and the results were included in our last report. Analysis with updated MarketScan database (including data from 2016) is ongoing. We are close to finalizing agreements with Canadian Partnership for Tomorrow Cohorts (CPTP) the Ontario Health Study and the BC Generations Project, as well as with the Canadian Institute for Health Information (CIHI)’s National Prescription Drug Utilization Information System Metadata (NPDUIS). This will provide updated analysis on new agents. We have also initiated an application with CPTP’s Alberta’s Tomorrow Project as well as beginning the process to access administrative health data from Manitoba.

Moura et al. Safety of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections for the treatment of patients with age-related macular degeneration (AMD). 2017 (ICPE abstract)

Machado et al. Safety of intravitreal injections for the treatment of patients with diabetic retinopathy: a population-based study. 2017 (ICPE abstract)

Full report submitted to DSEN and query submitters.

For more information contact: Autumn Neville. Research Coordinator. [email protected]   514.934.1934 ext.44844  or  ext.44718